ACS Chemical Biology · 2018 · 52 citations · 40 references
MedicineImmunologyOncologyCancer ImmunologyImmunotherapyTumor ImmunologyAntitumor T Cell ResponsesCancer ImmunotherapyCancer VaccinesConjugate VaccinesCytotoxic T Lymphocyte ResponsesHumoral ImmunityAnticancer ActivityCancer-associated MucinsImmunogenicity Of Tumor AntigensMucin AntigensMucin BiologyT-cell Mediated ImmunityTumor Antibody ResponsesTumor-associated Antigen Targeting
Mucin-1 (MUC1) is one of the top ranked tumor associated antigens. In order to generate effective anti-MUC1 immune responses as potential anticancer vaccines, MUC1 peptides and glycopeptides have been covalently conjugated to bacteriophage Qβ. Immunization of mice with these constructs led to highly potent antibody responses with IgG titers over one million, which are among the highest anti-MUC1 IgG titers reported to date. Furthermore, the high IgG antibody levels persisted for more than six months. The constructs also elicited MUC1 specific cytotoxic T cells, which can selectively kill MUC1 positive tumor cells. The unique abilities of Qβ-MUC1 conjugates to powerfully induce both antibody and cytotoxic T cell immunity targeting tumor cells bode well for future translation of the constructs as anticancer vaccines.
40
The Influence of Antigen Organization on B Cell Responsiveness
Martin F. Bachmann, Urs Hoffmann Rohrer, Thomas M. Kündig et al. · Science · 1993 · 731 citations
Vani Lakshminarayanan, Pamela Thompson, Margreet A. Wolfert et al. · Proceedings of the National Academy of Sciences · 2011 · 300 citations · Full text
Life Sciences, Immunology, Oncology +17
Cancer Biomarkers Defined by Autoantibody Signatures to Aberrant O-Glycopeptide Epitopes
Hans H. Wandall, Ola Blixt, Mads A. Tarp et al. · Cancer Research · 2010 · 277 citations · Full text
Life Sciences, Immunology, Oncology +17